Document Mentions (4 shared documents)

EFTA00370773

4 mentions1 same-page

Page ?Same page

From: Lesley Groff To: Jeffrey Epstein <[email protected]> Subject: Fwd: ATorus Daily Portfolio Report - 4/22 & 4/23 Date: Thu, 24 Apr 2014 12:46:25 +0000 Attachments: PeopleRandomn

From: Lesley Groff To: Jeffrey Epstein <[email protected]> Subject: Fwd: ATorus Dai

From: Lesley Groff To: Jeffrey Epstein <[email protected]> Subject: Fwd: AT

e a good day. - Daily Commentary - One of our pet peeves is people detecting patterns where there may be none. Reading the following article about Allergen takeover volume spike (Flurry of Allergan Trading Preceded Offer) is a case in point. And this is not say the article or the analysis (especially s

EFTA00821594

3 mentions1 same-page

Page ?Same page

ns' ;)id:image001.png@01D1B4D 2.34B2F410 From: jeffrey E. [mailto:jPeyacationghgmatISQM) Sent Monday, Aug

ns' ;)id:image001.png@01D1B4D 2.34B2F410 From: jeffrey E. [mailto:jPeyacationghgmatISQM) Sent Monday, Augu

version ratio sliding scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergen, Teva and Frontier Communications are three names we have high conviction on and they have mandatory convert preferreds that I recommend buying. All

EFTA00822153

2 mentions1 same-page

Page ?Same page

005.jpg: imagc006.jpg: image007.jpg: image008.jpg: image009.jpg: intage010.gie imagc011.png: image003.jpg: imagc015.jpg: image016.jpg: image017.jpg Jeffrey, Rich mentioned you're interested in potentially buying preferreds. While they still pay a decent yield. I wanted to share some thoughts about why I